Zobrazeno 1 - 10
of 46
pro vyhledávání: '"Jerald Radich"'
Autor:
Fekadu Urgessa, Boki Lengiso, Aster Tsegaye, Amha Gebremedhin, Fozia Abdella, Fisihatsion Tadesse, Jerald Radich, Helen Nigussie, Teklu Kuru Gerbaba
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract Background In low-income countries there is insufficient evidence on hematological, clinical, cytogenetic and molecular profiles among new CML patients. Therefore, we performed this study among newly confirmed CML patients at Tikur Anbesa Sp
Externí odkaz:
https://doaj.org/article/76f11eb1e41b4e51aab2c83e06c2f55d
Autor:
David W. Woolston, Nathan D. Lee, Mazyar Shadman, Elena Latorre-Esteves, Xin Ray Tee, Jeanne Fredrickson, Brendan F. Kohrn, Chaitra Ujjani, Ashley Eckel, Brian Till, Min Fang, Jerald Radich, Ivana Bozic, Rosa Ana Risques, Cecilia C.S. Yeung
Publikováno v:
Haematologica, Vol 109, Iss 7 (2024)
Externí odkaz:
https://doaj.org/article/542a298ed0e44e0db8002b7784b77e69
Autor:
Jorge E. Cortes, Qian Jiang, Jianxiang Wang, Jianyu Weng, Huanling Zhu, Xiaoli Liu, Andreas Hochhaus, Dong-Wook Kim, Jerald Radich, Michael Savona, Patricia Martin-Regueira, Oumar Sy, Giuseppe Saglio
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
Early molecular response (EMR) at 3 months is predictive of improved overall survival (OS) and progression-free survival (PFS) in patients with chronic myeloid leukemia in the chronic phase (CML-CP). Although about one-third of patients treated with
Externí odkaz:
https://doaj.org/article/39e1a5de16144c2285b230f79c731665
Autor:
David W. Woolston, Nathan D. Lee, Mazyar Shadman, Elena Latorre-Esteves, Xin Ray Tee, Jeanne Fredrickson, Brendan F. Kohrn, Chaitra Ujjani, Ashley Eckel, Brian Till, Min Fang, Jerald Radich, Ivana Bozic, Rosa Ana Risques, Cecilia C.S. Yeung
Publikováno v:
Haematologica, Vol 109, Iss 3 (2023)
BTK inhibitors, Bcl-2 inhibitors, and other targeted therapies have significantly improved the outcomes of patients with chronic lymphocytic leukemia (CLL). With increased survivorship, monitoring disease and deciphering potential mechanisms of resis
Externí odkaz:
https://doaj.org/article/0f5b94b207804bfbba3755740dba5865
Autor:
Olga Sala-Torra, Shishir Reddy, Ling-Hong Hung, Lan Beppu, David Wu, Jerald Radich, Ka Yee Yeung, Cecilia C S Yeung
Publikováno v:
PLOS Global Public Health, Vol 3, Iss 9, p e0002267 (2023)
Recurrent gene fusions are common drivers of disease pathophysiology in leukemias. Identifying these structural variants helps stratify disease by risk and assists with therapy choice. Precise molecular diagnosis in low-and-middle-income countries (L
Externí odkaz:
https://doaj.org/article/6e77bb1d6af84557843a38610a4ff84e
Publikováno v:
JCO Global Oncology, Vol , Iss 7, Pp 1187-1193 (2021)
PURPOSEDespite the successes achieved in chronic myeloid leukemia (CML) with tyrosine kinase inhibitor (TKI) therapy, resistance remains an obstacle. The most common mechanism of resistance is the acquisition of a point mutation in the BCR-ABL kinase
Externí odkaz:
https://doaj.org/article/bbb9bd3238754c2791c69bfaa0fbc310
Autor:
Dawne N. Shelton, Prasanthi Bhagavatula, Nathan Sepulveda, Lan Beppu, Shital Gandhi, Dahui Qin, Scott Hauenstein, Jerald Radich
Publikováno v:
PLoS ONE, Vol 17, Iss 3 (2022)
Chronic myelogenous leukemia (CML) is a hematopoietic stem cell malignancy that accounts for 15–20% of all cases of leukemia. CML is caused by a translocation between chromosomes 9 and 22 which creates an abnormal fusion gene, BCR::ABL1. The amount
Externí odkaz:
https://doaj.org/article/4d443c1627274a07bfe43da9290c2000
Autor:
Jerald Radich
Publikováno v:
Haematologica, Vol 103, Iss 12 (2018)
Externí odkaz:
https://doaj.org/article/acacab73427f486bb34b69bcd93cd10e
Autor:
Sabrina Angelini, Simona Soverini, Gloria Ravegnini, Matt Barnett, Eleonora Turrini, Mark Thornquist, Fabrizio Pane, Timothy P. Hughes, Deborah L. White, Jerald Radich, Dong Wook Kim, Giuseppe Saglio, Daniela Cilloni, Ilaria Iacobucci, Giovanni Perini, Richard Woodman, Giorgio Cantelli-Forti, Michele Baccarani, Patrizia Hrelia, Giovanni Martinelli
Publikováno v:
Haematologica, Vol 98, Iss 2 (2013)
Imatinib has so far been the first-choice treatment in chronic myeloid leukemia with excellent results. However, only a proportion of patients achieve major molecular response – hence the need to find biological predictors of outcome to select the
Externí odkaz:
https://doaj.org/article/8fede9d6b6b34a01878c34770c38ed9a
Autor:
Deborah L. White, Jerald Radich, Simona Soverini, Verity A Saunders, Amity K. Frede, Phuong Dang, Daniela Cilloni, Peter Lin, Lidia Mongay, Richard Woodman, Paul Manley, Cassandra Slader, Dong Wook Kim, Fabrizio Pane, Giovanni Martinelli, Giuseppe Saglio, Timothy P. Hughes
Publikováno v:
Haematologica, Vol 97, Iss 6 (2012)
Background The functional activity of the organic cation transporter 1 (OCT-1) protein (OCT-1 activity) is an excellent predictor of molecular response and progression-free survival in patients with newly diagnosed chronic phase chronic myeloid leuke
Externí odkaz:
https://doaj.org/article/c9ad3ceda3a94149b72205c47d2cb76d